Report on Annual General Meeting held in NeuroSearch A/S
| Source:NeuroSearch A/S
At the company's Annual General Meeting today, the following decisions were taken:
The NeuroSearch Annual Report 2012 was adopted
The Board of Director’s proposal regarding the transfer of profits and losses for 2012 to next year was adopted
The Board of Directors was re-elected and thus still consists of Allan Andersen (Chairman), Torbjörn Bjerke and Christian Lundgren as well as the employee representatives Lars Siim Madsen and Morten Henrik Nielsen
PricewaterhouseCoopers was re-elected as the company's auditor
The general meeting authorised the Board to purchase own shares of up to a total nominal value of DKK 2,455,394 (corresponding to 10% of the company's present share capital) in the period until the next Annual General Meeting
The proposed fee to the Board of Directors for 2013 was adopted.
Chairman of the Board of Directors
René Schneider, CEO, telephone: +45 2911 2097
AboutNeuroSearch NeuroSearch A/S (NEUR) is listed on NASDAQ OMX Copenhagen A/S. The company’s product pipeline comprises ordopidine and seridopidine, which have both completed phase I studies, as well as tesofensine, which has completed phase II, and NS2359 which has completed phase I. All drug candidates exert their effect in the central nervous system.
GlobeNewswire, a NASDAQ OMX company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.